Anti-matrix metalloproteinase-9 DNAzyme decreases tumor growth in the MMTV-PyMT mouse model of breast cancer

Breast Cancer Research

Volumn 15, Issue 1, 2013, Pages

  Hallett, Miranda A ^a   Teng, Bin ^a   Hasegawa, Hisashi ^a   Schwab, Luciana P ^a   Seagroves, Tiffany N ^a   Pourmotabbed, Tayebeh ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMATRIX METALLOPROTEINASE 9 DNAZYME; ANTINEOPLASTIC AGENT; DNAZYME; FLUORESCENT DYE; GELATINASE B; OLIGONUCLEOTIDE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; ANTI-MMP-9 DNAZYME; DEOXYRIBOZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CANCER SIZE; CANCER TISSUE; CELL INVASION; CONTROLLED STUDY; ENZYME STABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MAMMARY NEOPLASMS, ANIMAL; METASTASIS; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DNA, CATALYTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS;

EID: 84876068534     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3385     Document Type: Article

References (49)

1. American Cancer Society Breast Cancer Facts and Figures 2007-2008. American Cancer Society, Inc 2009, Atlanta, GA, American Cancer Society., http://www.cancer.org
2. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005, 5:591-602.
3. Phadke PA, Vaidya KS, Nash KT, Hurst DR, Welch DR. BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol 2008, 172:809-817. 10.2353/ajpath.2008.070772, 2258257, 18276787.
4. Sethi N, Kang Y. Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer 2011, 11:735-748. 10.1038/nrc3125, 21941285.
5. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002, 2:563-572. 10.1038/nrc865, 12154349.
6. Gavrilovic J, Moens G, Thiery JP, Jouanneau J. Expression of transfected transforming growth factor alpha induces a motile fibroblast-like phenotype with extracellular matrix-degrading potential in a rat bladder carcinoma cell line. Cell Regul 1990, 1:1003-1014. 361698, 2134746.
7. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997, 139:1861-1872. 10.1083/jcb.139.7.1861, 2132651, 9412478.
8. Noel A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumor-host interface. Semin Cell Dev Biol 2008, 19:52-60. 10.1016/j.semcdb.2007.05.011, 17625931.
9. Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J Cell Sci 2005, 118:2143-2153. 10.1242/jcs.02334, 15855236.
10. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174. 10.1038/nrc745, 11990853.
11. Watanabe H, Nakanishi I, Yamashita K, Hayakawa T, Okada Y. Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. J Cell Sci 1993, 104(Pt 4):991-999.
12. Cha HJ, Bae SK, Lee HY, Lee OH, Sato H, Seiki M, Park BC, Kim KW. Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res 1996, 56:2281-2284.
13. Fenhalls G, Geyp M, Dent DM, Parker MI. Breast tumour cell-induced down-regulation of type I collagen mRNA in fibroblasts. Br J Cancer 1999, 81:1142-1149. 10.1038/sj.bjc.6690821, 2374322, 10584874.
14. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol 1996, 3:895-904. 10.1016/S1074-5521(96)90178-7, 8939708.
15. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003, 3:489-501. 10.1038/nrc1121, 12835669.
16. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003, 89:1817-1821. 10.1038/sj.bjc.6601327, 2394437, 14612884.
17. Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, Lakka SS. Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem 2008, 283:1545-1552. 2206181, 17991734.
18. Matrisian LM, Bowden GT, Krieg P, Furstenberger G, Briand JP, Leroy P, Breathnach R. The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors. Proc Natl Acad Sci USA 1986, 83:9413-9417. 10.1073/pnas.83.24.9413, 387148, 3540938.
19. Liotta LA, Rao CN, Wewer UM. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986, 55:1037-1057. 10.1146/annurev.bi.55.070186.005133, 3017189.
20. Chintala SK, Tonn JC, Rao JS. Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 1999, 17:495-502. 10.1016/S0736-5748(99)00010-6, 10571411.
21. Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, Noonan DM, Natali PG, Albini A. The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000, 87:336-342. 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3, 10897037.
22. Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 1994, 91:4293-4297. 10.1073/pnas.91.10.4293, 43771, 8183903.
23. Santoro SW, Joyce GF. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 1998, 37:13330-13342. 10.1021/bi9812221, 9748341.
24. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997, 94:4262-4266. 10.1073/pnas.94.9.4262, 20710, 9113977.
25. Dass CR, Choong PF, Khachigian LM. DNAzyme technology and cancer therapy: cleave and let die. Mol Cancer Ther 2008, 7:243-251.
26. Lowe HC, Fahmy RG, Kavurma MM, Baker A, Chesterman CN, Khachigian LM. Catalytic oligodeoxynucleotides define a key regulatory role for early growth response factor-1 in the porcine model of coronary in-stent restenosis. Circ Res 2001, 89:670-677. 10.1161/hh2001.097867, 11597989.
27. Khachigian LM, Fahmy RG, Zhang G, Bobryshev YV, Kaniaros A. c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury. Inhibition by a novel DNA enzyme targeting c-Jun. J Biol Chem 2002, 277:22985-22991. 10.1074/jbc.M200977200, 11891228.
28. Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res 2002, 62:5463-5469.
29. Sun LQ, Cairns MJ, Saravolac EG, Baker A, Gerlach WL. Catalytic nucleic acids: from lab to applications. Pharmacol Rev 2000, 52:325-347.
30. Hegedüs L, Cho H, Xie X, Eliceiri GL. Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol 2008, 216:480-485. 10.1002/jcp.21417, 18286480.
31. Bu CH, Pourmotabbed T. Mechanism of activation of human neutrophil gelatinase B: Discriminating between the role of Ca in activation and catalytsis. J Biol Chem 1995, (270):18563-18569.
32. Chantrain CF, DeClerck YA, Groshen S, McNamara G. Computerized quantification of tissue vascularization using high-resolution slide scanning of whole tumor sections. J Histochem Cytochem 2003, 51:151-158. 10.1177/002215540305100203, 12533523.
33. Yodkeeree S, Ampasavate C, Sung B, Aggarwal BB, Limtrakul P. Demethoxycurcumin suppresses migration and invasion of MDA-MB-231 human breast cancer cell line. Eur J Pharmacol 2010, 627:8-15. 10.1016/j.ejphar.2009.09.052, 19818349.
34. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003, 163:2113-2126. 10.1016/S0002-9440(10)63568-7, 1892434, 14578209.
35. Fantozzi A, Christofori G. Mouse models of breast cancer metastasis. Breast Cancer Res 2006, 8:212. 10.1186/bcr1530, 1779475, 16887003.
36. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov IA, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L, Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Dyke TV, Perou CM. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76. 10.1186/gb-2007-8-5-r76, 1929138, 17493263.
37. Pedersen TX, Pennington CJ, Almholt K, Christensen IJ, Nielsen BS, Edwards DR, Romer J, Dano K, Johnsen M. Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis 2005, 26:1233-1240.
38. Szabova L, Yamada SS, Birkedal-Hansen H, Holmbeck K. Expression pattern of four membrane-type matrix metalloproteinases in the normal and diseased mouse mammary gland. J Cell Physiol 2005, 205:123-132. 10.1002/jcp.20385, 15895410.
39. Almholt K, Green KA, Juncker-Jensen A, Nielsen BS, Lund LR, Romer J. Extracellular proteolysis in transgenic mouse models of breast cancer. J Mammary Gland Biol Neoplasia 2007, 12:83-97. 10.1007/s10911-007-9040-x, 1820839, 17286208.
40. Almholt K, Juncker-Jensen A, Laerum OD, Dano K, Johnsen M, Lund LR, Romer J. Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Mol Cancer Ther 2008, 7:2758-2767. 10.1158/1535-7163.MCT-08-0251, 18790756.
41. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740. 10.1084/jem.193.6.727, 2193412, 11257139.
42. Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 2002, 7:147-162. 10.1023/A:1020399802795, 12465600.
43. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2:737-744. 10.1038/35036374, 2852586, 11025665.
44. Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, Thiolloy S, Lynch CC, Matrisian LM, Fingleton B. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 2008, 68:6251-6259. 10.1158/0008-5472.CAN-08-0537, 2789265, 18676849.
45. Smyth E. The trouble with inhibitors. Signalling Scissors: New Perspectives on Proteases, Horizon Symposia, Brescia, Italy, Nature Publishing Group 2003, 1-4., http://www.nature.com/horizon/proteases/background/pdf/inhibitors.pdf
46. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997, 15:61-75. 10.1023/A:1005722729132, 9195290.
47. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997, 75:69-75. 10.1016/S0163-7258(97)00023-5, 9364582.
48. Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007, 26:717-724. 10.1007/s10555-007-9089-4, 17717634.
49. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392. 10.1126/science.1067100, 11923519.